Since joining Kirkland, Brianne has been involved in the following representations:
- Avidity Biosciences in its pending $12 billion sale to Novartis, and the related spin-off of its early-stage precision cardiology programs
Prior to joining Kirkland, Brianne was involved in the following representations:
- SiteOne Therapeutics in its acquisition by Eli Lilly for up to $1 billion
- The special committee of the board of directors of AspenTech in its $7.2 billion sale to Emerson Electric of all shares of AspenTech not already owned by Emerson
- EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
- The special committee of the board of directors of EngageSmart in its $4 billion sale to Vista Equity Partners
- Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
- POINT Biopharma in its $1.4 billion acquisition by Eli Lilly
- IVERIC Bio in its $5.9 billion sale to Astellas
- Kelso & Company in its sale of Refresh Mental Health to Optum, a division of UnitedHealthcare
- Dicerna Pharmaceuticals in its sale to Novo Nordisk for $3.3 billion
